nodes	percent_of_prediction	percent_of_DWPC	metapath
Nevirapine—CYP1A2—Pentoxifylline—systemic scleroderma	0.122	0.209	CbGbCtD
Nevirapine—CYP1A2—Leflunomide—systemic scleroderma	0.116	0.2	CbGbCtD
Nevirapine—CYP2C9—Leflunomide—systemic scleroderma	0.105	0.18	CbGbCtD
Nevirapine—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.0964	0.166	CbGbCtD
Nevirapine—CYP2D6—Captopril—systemic scleroderma	0.0751	0.129	CbGbCtD
Nevirapine—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0376	0.0646	CbGbCtD
Nevirapine—CYP3A4—Prednisone—systemic scleroderma	0.03	0.0517	CbGbCtD
Nevirapine—CYP2C9—cardial valve—systemic scleroderma	0.00253	0.675	CbGeAlD
Nevirapine—Skin disorder—Azathioprine—systemic scleroderma	0.000601	0.00145	CcSEcCtD
Nevirapine—Vomiting—Pentoxifylline—systemic scleroderma	0.000595	0.00143	CcSEcCtD
Nevirapine—Lymphadenopathy—Methotrexate—systemic scleroderma	0.000594	0.00143	CcSEcCtD
Nevirapine—Rash—Pentoxifylline—systemic scleroderma	0.00059	0.00142	CcSEcCtD
Nevirapine—Dermatitis—Pentoxifylline—systemic scleroderma	0.000589	0.00142	CcSEcCtD
Nevirapine—Headache—Pentoxifylline—systemic scleroderma	0.000586	0.00141	CcSEcCtD
Nevirapine—Face oedema—Prednisone—systemic scleroderma	0.000586	0.00141	CcSEcCtD
Nevirapine—Anaphylactic shock—Leflunomide—systemic scleroderma	0.000584	0.00141	CcSEcCtD
Nevirapine—Feeling abnormal—Captopril—systemic scleroderma	0.000584	0.00141	CcSEcCtD
Nevirapine—Arthralgia—Mycophenolic acid—systemic scleroderma	0.000581	0.0014	CcSEcCtD
Nevirapine—Myalgia—Mycophenolic acid—systemic scleroderma	0.000581	0.0014	CcSEcCtD
Nevirapine—Gastrointestinal pain—Captopril—systemic scleroderma	0.00058	0.0014	CcSEcCtD
Nevirapine—Asthenia—Mometasone—systemic scleroderma	0.000579	0.0014	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000577	0.00139	CcSEcCtD
Nevirapine—Discomfort—Mycophenolic acid—systemic scleroderma	0.000574	0.00138	CcSEcCtD
Nevirapine—Nervous system disorder—Leflunomide—systemic scleroderma	0.000573	0.00138	CcSEcCtD
Nevirapine—Thrombocytopenia—Leflunomide—systemic scleroderma	0.000572	0.00138	CcSEcCtD
Nevirapine—Pruritus—Mometasone—systemic scleroderma	0.000571	0.00138	CcSEcCtD
Nevirapine—Ill-defined disorder—Lisinopril—systemic scleroderma	0.000571	0.00138	CcSEcCtD
Nevirapine—Anaemia—Lisinopril—systemic scleroderma	0.000569	0.00137	CcSEcCtD
Nevirapine—Skin disorder—Leflunomide—systemic scleroderma	0.000568	0.00137	CcSEcCtD
Nevirapine—Hepatic failure—Methotrexate—systemic scleroderma	0.000564	0.00136	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.000564	0.00136	CcSEcCtD
Nevirapine—Angioedema—Lisinopril—systemic scleroderma	0.000562	0.00135	CcSEcCtD
Nevirapine—Body temperature increased—Captopril—systemic scleroderma	0.00056	0.00135	CcSEcCtD
Nevirapine—Abdominal pain—Captopril—systemic scleroderma	0.00056	0.00135	CcSEcCtD
Nevirapine—Oedema—Mycophenolic acid—systemic scleroderma	0.000557	0.00134	CcSEcCtD
Nevirapine—Anorexia—Leflunomide—systemic scleroderma	0.000557	0.00134	CcSEcCtD
Nevirapine—Nausea—Pentoxifylline—systemic scleroderma	0.000556	0.00134	CcSEcCtD
Nevirapine—Malaise—Lisinopril—systemic scleroderma	0.000555	0.00134	CcSEcCtD
Nevirapine—Diarrhoea—Mometasone—systemic scleroderma	0.000552	0.00133	CcSEcCtD
Nevirapine—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000547	0.00132	CcSEcCtD
Nevirapine—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000546	0.00132	CcSEcCtD
Nevirapine—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000541	0.00131	CcSEcCtD
Nevirapine—Dermatitis exfoliative—Methotrexate—systemic scleroderma	0.000537	0.0013	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.000535	0.00129	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000534	0.00129	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000532	0.00128	CcSEcCtD
Nevirapine—Anorexia—Mycophenolic acid—systemic scleroderma	0.000531	0.00128	CcSEcCtD
Nevirapine—Paraesthesia—Leflunomide—systemic scleroderma	0.000525	0.00126	CcSEcCtD
Nevirapine—Arthralgia—Lisinopril—systemic scleroderma	0.000524	0.00126	CcSEcCtD
Nevirapine—Myalgia—Lisinopril—systemic scleroderma	0.000524	0.00126	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00052	0.00125	CcSEcCtD
Nevirapine—Discomfort—Lisinopril—systemic scleroderma	0.000517	0.00125	CcSEcCtD
Nevirapine—Pancreatitis—Prednisone—systemic scleroderma	0.000514	0.00124	CcSEcCtD
Nevirapine—Vomiting—Mometasone—systemic scleroderma	0.000513	0.00124	CcSEcCtD
Nevirapine—Feeling abnormal—Azathioprine—systemic scleroderma	0.00051	0.00123	CcSEcCtD
Nevirapine—Rash—Mometasone—systemic scleroderma	0.000509	0.00123	CcSEcCtD
Nevirapine—Asthenia—Captopril—systemic scleroderma	0.000509	0.00123	CcSEcCtD
Nevirapine—Dermatitis—Mometasone—systemic scleroderma	0.000508	0.00123	CcSEcCtD
Nevirapine—Decreased appetite—Leflunomide—systemic scleroderma	0.000508	0.00122	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000508	0.00122	CcSEcCtD
Nevirapine—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000506	0.00122	CcSEcCtD
Nevirapine—Headache—Mometasone—systemic scleroderma	0.000506	0.00122	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000504	0.00122	CcSEcCtD
Nevirapine—Fatigue—Leflunomide—systemic scleroderma	0.000504	0.00121	CcSEcCtD
Nevirapine—Oedema—Lisinopril—systemic scleroderma	0.000502	0.00121	CcSEcCtD
Nevirapine—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000502	0.00121	CcSEcCtD
Nevirapine—Pruritus—Captopril—systemic scleroderma	0.000502	0.00121	CcSEcCtD
Nevirapine—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.0005	0.00121	CcSEcCtD
Nevirapine—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.0005	0.00121	CcSEcCtD
Nevirapine—Pain—Leflunomide—systemic scleroderma	0.0005	0.0012	CcSEcCtD
Nevirapine—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000498	0.0012	CcSEcCtD
Nevirapine—Somnolence—Mycophenolic acid—systemic scleroderma	0.000496	0.00119	CcSEcCtD
Nevirapine—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000492	0.00119	CcSEcCtD
Nevirapine—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000492	0.00118	CcSEcCtD
Nevirapine—Neutropenia—Prednisone—systemic scleroderma	0.00049	0.00118	CcSEcCtD
Nevirapine—Abdominal pain—Azathioprine—systemic scleroderma	0.000489	0.00118	CcSEcCtD
Nevirapine—Body temperature increased—Azathioprine—systemic scleroderma	0.000489	0.00118	CcSEcCtD
Nevirapine—Skin disorder—Lisinopril—systemic scleroderma	0.000488	0.00118	CcSEcCtD
Nevirapine—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000486	0.00117	CcSEcCtD
Nevirapine—Diarrhoea—Captopril—systemic scleroderma	0.000485	0.00117	CcSEcCtD
Nevirapine—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000485	0.00117	CcSEcCtD
Nevirapine—Feeling abnormal—Leflunomide—systemic scleroderma	0.000481	0.00116	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000481	0.00116	CcSEcCtD
Nevirapine—Fatigue—Mycophenolic acid—systemic scleroderma	0.000481	0.00116	CcSEcCtD
Nevirapine—Nausea—Mometasone—systemic scleroderma	0.000479	0.00116	CcSEcCtD
Nevirapine—Anorexia—Lisinopril—systemic scleroderma	0.000479	0.00115	CcSEcCtD
Nevirapine—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000478	0.00115	CcSEcCtD
Nevirapine—Pain—Mycophenolic acid—systemic scleroderma	0.000477	0.00115	CcSEcCtD
Nevirapine—Hyperglycaemia—Prednisone—systemic scleroderma	0.000473	0.00114	CcSEcCtD
Nevirapine—Liver function test abnormal—Methotrexate—systemic scleroderma	0.000468	0.00113	CcSEcCtD
Nevirapine—Urticaria—Leflunomide—systemic scleroderma	0.000464	0.00112	CcSEcCtD
Nevirapine—Abdominal pain—Leflunomide—systemic scleroderma	0.000462	0.00111	CcSEcCtD
Nevirapine—Body temperature increased—Leflunomide—systemic scleroderma	0.000462	0.00111	CcSEcCtD
Nevirapine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000459	0.00111	CcSEcCtD
Nevirapine—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000459	0.00111	CcSEcCtD
Nevirapine—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000459	0.00111	CcSEcCtD
Nevirapine—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000458	0.0011	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000457	0.0011	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000457	0.0011	CcSEcCtD
Nevirapine—Hypersensitivity—Azathioprine—systemic scleroderma	0.000456	0.0011	CcSEcCtD
Nevirapine—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000456	0.0011	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000456	0.0011	CcSEcCtD
Nevirapine—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000453	0.00109	CcSEcCtD
Nevirapine—Paraesthesia—Lisinopril—systemic scleroderma	0.000451	0.00109	CcSEcCtD
Nevirapine—Vomiting—Captopril—systemic scleroderma	0.000451	0.00109	CcSEcCtD
Nevirapine—Rash—Captopril—systemic scleroderma	0.000447	0.00108	CcSEcCtD
Nevirapine—Dermatitis—Captopril—systemic scleroderma	0.000447	0.00108	CcSEcCtD
Nevirapine—Somnolence—Lisinopril—systemic scleroderma	0.000446	0.00108	CcSEcCtD
Nevirapine—Headache—Captopril—systemic scleroderma	0.000444	0.00107	CcSEcCtD
Nevirapine—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000441	0.00106	CcSEcCtD
Nevirapine—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000441	0.00106	CcSEcCtD
Nevirapine—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.00044	0.00106	CcSEcCtD
Nevirapine—Oedema—Mycophenolate mofetil—systemic scleroderma	0.00044	0.00106	CcSEcCtD
Nevirapine—Decreased appetite—Lisinopril—systemic scleroderma	0.000436	0.00105	CcSEcCtD
Nevirapine—Eosinophilia—Methotrexate—systemic scleroderma	0.000434	0.00105	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000433	0.00104	CcSEcCtD
Nevirapine—Fatigue—Lisinopril—systemic scleroderma	0.000433	0.00104	CcSEcCtD
Nevirapine—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000431	0.00104	CcSEcCtD
Nevirapine—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000431	0.00104	CcSEcCtD
Nevirapine—Hypersensitivity—Leflunomide—systemic scleroderma	0.00043	0.00104	CcSEcCtD
Nevirapine—Pancreatitis—Methotrexate—systemic scleroderma	0.00043	0.00104	CcSEcCtD
Nevirapine—Pain—Lisinopril—systemic scleroderma	0.000429	0.00103	CcSEcCtD
Nevirapine—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000427	0.00103	CcSEcCtD
Nevirapine—Diarrhoea—Azathioprine—systemic scleroderma	0.000423	0.00102	CcSEcCtD
Nevirapine—Nausea—Captopril—systemic scleroderma	0.000421	0.00102	CcSEcCtD
Nevirapine—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000419	0.00101	CcSEcCtD
Nevirapine—Asthenia—Leflunomide—systemic scleroderma	0.000419	0.00101	CcSEcCtD
Nevirapine—Feeling abnormal—Lisinopril—systemic scleroderma	0.000414	0.000997	CcSEcCtD
Nevirapine—Pruritus—Leflunomide—systemic scleroderma	0.000413	0.000996	CcSEcCtD
Nevirapine—Connective tissue disorder—Prednisone—systemic scleroderma	0.000412	0.000994	CcSEcCtD
Nevirapine—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000411	0.00099	CcSEcCtD
Nevirapine—Neutropenia—Methotrexate—systemic scleroderma	0.00041	0.000988	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000401	0.000966	CcSEcCtD
Nevirapine—Asthenia—Mycophenolic acid—systemic scleroderma	0.0004	0.000964	CcSEcCtD
Nevirapine—Diarrhoea—Leflunomide—systemic scleroderma	0.0004	0.000964	CcSEcCtD
Nevirapine—Urticaria—Lisinopril—systemic scleroderma	0.000399	0.000961	CcSEcCtD
Nevirapine—Abdominal pain—Lisinopril—systemic scleroderma	0.000397	0.000957	CcSEcCtD
Nevirapine—Body temperature increased—Lisinopril—systemic scleroderma	0.000397	0.000957	CcSEcCtD
Nevirapine—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000395	0.000952	CcSEcCtD
Nevirapine—Pruritus—Mycophenolic acid—systemic scleroderma	0.000394	0.000951	CcSEcCtD
Nevirapine—Vomiting—Azathioprine—systemic scleroderma	0.000393	0.000948	CcSEcCtD
Nevirapine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000391	0.000943	CcSEcCtD
Nevirapine—Rash—Azathioprine—systemic scleroderma	0.00039	0.00094	CcSEcCtD
Nevirapine—Dermatitis—Azathioprine—systemic scleroderma	0.00039	0.000939	CcSEcCtD
Nevirapine—Headache—Azathioprine—systemic scleroderma	0.000388	0.000934	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000387	0.000934	CcSEcCtD
Nevirapine—Renal failure—Methotrexate—systemic scleroderma	0.000384	0.000926	CcSEcCtD
Nevirapine—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000382	0.000922	CcSEcCtD
Nevirapine—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000381	0.000919	CcSEcCtD
Nevirapine—Conjunctivitis—Methotrexate—systemic scleroderma	0.00038	0.000915	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00038	0.000915	CcSEcCtD
Nevirapine—Immune system disorder—Prednisone—systemic scleroderma	0.000379	0.000914	CcSEcCtD
Nevirapine—Pain—Mycophenolate mofetil—systemic scleroderma	0.000376	0.000907	CcSEcCtD
Nevirapine—Vomiting—Leflunomide—systemic scleroderma	0.000371	0.000895	CcSEcCtD
Nevirapine—Hypersensitivity—Lisinopril—systemic scleroderma	0.00037	0.000892	CcSEcCtD
Nevirapine—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.00037	0.000891	CcSEcCtD
Nevirapine—Rash—Leflunomide—systemic scleroderma	0.000368	0.000888	CcSEcCtD
Nevirapine—Dermatitis—Leflunomide—systemic scleroderma	0.000368	0.000887	CcSEcCtD
Nevirapine—Nausea—Azathioprine—systemic scleroderma	0.000367	0.000886	CcSEcCtD
Nevirapine—Headache—Leflunomide—systemic scleroderma	0.000366	0.000882	CcSEcCtD
Nevirapine—Erythema—Prednisone—systemic scleroderma	0.000365	0.000881	CcSEcCtD
Nevirapine—Agranulocytosis—Methotrexate—systemic scleroderma	0.000365	0.000879	CcSEcCtD
Nevirapine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000362	0.000874	CcSEcCtD
Nevirapine—Asthenia—Lisinopril—systemic scleroderma	0.00036	0.000868	CcSEcCtD
Nevirapine—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00036	0.000867	CcSEcCtD
Nevirapine—Pruritus—Lisinopril—systemic scleroderma	0.000355	0.000856	CcSEcCtD
Nevirapine—Vomiting—Mycophenolic acid—systemic scleroderma	0.000354	0.000854	CcSEcCtD
Nevirapine—Rash—Mycophenolic acid—systemic scleroderma	0.000351	0.000847	CcSEcCtD
Nevirapine—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000351	0.000846	CcSEcCtD
Nevirapine—Hepatitis—Methotrexate—systemic scleroderma	0.000351	0.000845	CcSEcCtD
Nevirapine—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000349	0.000842	CcSEcCtD
Nevirapine—Headache—Mycophenolic acid—systemic scleroderma	0.000349	0.000842	CcSEcCtD
Nevirapine—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000348	0.000838	CcSEcCtD
Nevirapine—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000348	0.000838	CcSEcCtD
Nevirapine—Nausea—Leflunomide—systemic scleroderma	0.000347	0.000837	CcSEcCtD
Nevirapine—Diarrhoea—Lisinopril—systemic scleroderma	0.000344	0.000828	CcSEcCtD
Nevirapine—Ill-defined disorder—Prednisone—systemic scleroderma	0.000339	0.000817	CcSEcCtD
Nevirapine—Anaemia—Prednisone—systemic scleroderma	0.000338	0.000814	CcSEcCtD
Nevirapine—Angioedema—Prednisone—systemic scleroderma	0.000334	0.000805	CcSEcCtD
Nevirapine—Erythema multiforme—Methotrexate—systemic scleroderma	0.000332	0.000799	CcSEcCtD
Nevirapine—Nausea—Mycophenolic acid—systemic scleroderma	0.000331	0.000798	CcSEcCtD
Nevirapine—Malaise—Prednisone—systemic scleroderma	0.000329	0.000794	CcSEcCtD
Nevirapine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000324	0.000781	CcSEcCtD
Nevirapine—Vomiting—Lisinopril—systemic scleroderma	0.000319	0.000769	CcSEcCtD
Nevirapine—Immune system disorder—Methotrexate—systemic scleroderma	0.000317	0.000764	CcSEcCtD
Nevirapine—Rash—Lisinopril—systemic scleroderma	0.000317	0.000763	CcSEcCtD
Nevirapine—Dermatitis—Lisinopril—systemic scleroderma	0.000316	0.000762	CcSEcCtD
Nevirapine—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000316	0.000761	CcSEcCtD
Nevirapine—Headache—Lisinopril—systemic scleroderma	0.000315	0.000758	CcSEcCtD
Nevirapine—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000311	0.00075	CcSEcCtD
Nevirapine—Arthralgia—Prednisone—systemic scleroderma	0.000311	0.00075	CcSEcCtD
Nevirapine—Myalgia—Prednisone—systemic scleroderma	0.000311	0.00075	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000309	0.000745	CcSEcCtD
Nevirapine—Discomfort—Prednisone—systemic scleroderma	0.000307	0.000741	CcSEcCtD
Nevirapine—Erythema—Methotrexate—systemic scleroderma	0.000305	0.000736	CcSEcCtD
Nevirapine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000301	0.000725	CcSEcCtD
Nevirapine—Nausea—Lisinopril—systemic scleroderma	0.000298	0.000719	CcSEcCtD
Nevirapine—Oedema—Prednisone—systemic scleroderma	0.000298	0.000719	CcSEcCtD
Nevirapine—Anaphylactic shock—Prednisone—systemic scleroderma	0.000298	0.000719	CcSEcCtD
Nevirapine—Nervous system disorder—Prednisone—systemic scleroderma	0.000292	0.000705	CcSEcCtD
Nevirapine—Skin disorder—Prednisone—systemic scleroderma	0.00029	0.000698	CcSEcCtD
Nevirapine—Anorexia—Prednisone—systemic scleroderma	0.000284	0.000685	CcSEcCtD
Nevirapine—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000283	0.000683	CcSEcCtD
Nevirapine—Anaemia—Methotrexate—systemic scleroderma	0.000282	0.00068	CcSEcCtD
Nevirapine—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.00028	0.000674	CcSEcCtD
Nevirapine—Rash—Mycophenolate mofetil—systemic scleroderma	0.000277	0.000669	CcSEcCtD
Nevirapine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000277	0.000668	CcSEcCtD
Nevirapine—Headache—Mycophenolate mofetil—systemic scleroderma	0.000276	0.000664	CcSEcCtD
Nevirapine—Malaise—Methotrexate—systemic scleroderma	0.000275	0.000664	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000272	0.000655	CcSEcCtD
Nevirapine—Paraesthesia—Prednisone—systemic scleroderma	0.000268	0.000645	CcSEcCtD
Nevirapine—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000261	0.00063	CcSEcCtD
Nevirapine—Arthralgia—Methotrexate—systemic scleroderma	0.00026	0.000627	CcSEcCtD
Nevirapine—Myalgia—Methotrexate—systemic scleroderma	0.00026	0.000627	CcSEcCtD
Nevirapine—Decreased appetite—Prednisone—systemic scleroderma	0.000259	0.000625	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000258	0.000622	CcSEcCtD
Nevirapine—Fatigue—Prednisone—systemic scleroderma	0.000257	0.00062	CcSEcCtD
Nevirapine—Discomfort—Methotrexate—systemic scleroderma	0.000257	0.000619	CcSEcCtD
Nevirapine—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000249	0.000601	CcSEcCtD
Nevirapine—Feeling abnormal—Prednisone—systemic scleroderma	0.000246	0.000592	CcSEcCtD
Nevirapine—Nervous system disorder—Methotrexate—systemic scleroderma	0.000244	0.000589	CcSEcCtD
Nevirapine—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000244	0.000588	CcSEcCtD
Nevirapine—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000244	0.000588	CcSEcCtD
Nevirapine—Skin disorder—Methotrexate—systemic scleroderma	0.000242	0.000583	CcSEcCtD
Nevirapine—Anorexia—Methotrexate—systemic scleroderma	0.000238	0.000573	CcSEcCtD
Nevirapine—Urticaria—Prednisone—systemic scleroderma	0.000237	0.000571	CcSEcCtD
Nevirapine—Abdominal pain—Prednisone—systemic scleroderma	0.000236	0.000568	CcSEcCtD
Nevirapine—Body temperature increased—Prednisone—systemic scleroderma	0.000236	0.000568	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000227	0.000547	CcSEcCtD
Nevirapine—Paraesthesia—Methotrexate—systemic scleroderma	0.000224	0.000539	CcSEcCtD
Nevirapine—Somnolence—Methotrexate—systemic scleroderma	0.000222	0.000534	CcSEcCtD
Nevirapine—Hypersensitivity—Prednisone—systemic scleroderma	0.00022	0.00053	CcSEcCtD
Nevirapine—Decreased appetite—Methotrexate—systemic scleroderma	0.000217	0.000522	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000215	0.000519	CcSEcCtD
Nevirapine—Fatigue—Methotrexate—systemic scleroderma	0.000215	0.000518	CcSEcCtD
Nevirapine—Asthenia—Prednisone—systemic scleroderma	0.000214	0.000516	CcSEcCtD
Nevirapine—Pain—Methotrexate—systemic scleroderma	0.000213	0.000514	CcSEcCtD
Nevirapine—Pruritus—Prednisone—systemic scleroderma	0.000211	0.000509	CcSEcCtD
Nevirapine—Feeling abnormal—Methotrexate—systemic scleroderma	0.000205	0.000495	CcSEcCtD
Nevirapine—Diarrhoea—Prednisone—systemic scleroderma	0.000204	0.000492	CcSEcCtD
Nevirapine—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000204	0.000491	CcSEcCtD
Nevirapine—Urticaria—Methotrexate—systemic scleroderma	0.000198	0.000477	CcSEcCtD
Nevirapine—Abdominal pain—Methotrexate—systemic scleroderma	0.000197	0.000475	CcSEcCtD
Nevirapine—Body temperature increased—Methotrexate—systemic scleroderma	0.000197	0.000475	CcSEcCtD
Nevirapine—Vomiting—Prednisone—systemic scleroderma	0.00019	0.000457	CcSEcCtD
Nevirapine—Rash—Prednisone—systemic scleroderma	0.000188	0.000453	CcSEcCtD
Nevirapine—Dermatitis—Prednisone—systemic scleroderma	0.000188	0.000453	CcSEcCtD
Nevirapine—Headache—Prednisone—systemic scleroderma	0.000187	0.00045	CcSEcCtD
Nevirapine—Hypersensitivity—Methotrexate—systemic scleroderma	0.000184	0.000443	CcSEcCtD
Nevirapine—CYP2A6—lung—systemic scleroderma	0.000183	0.049	CbGeAlD
Nevirapine—Asthenia—Methotrexate—systemic scleroderma	0.000179	0.000431	CcSEcCtD
Nevirapine—Nausea—Prednisone—systemic scleroderma	0.000177	0.000427	CcSEcCtD
Nevirapine—Pruritus—Methotrexate—systemic scleroderma	0.000176	0.000425	CcSEcCtD
Nevirapine—Diarrhoea—Methotrexate—systemic scleroderma	0.00017	0.000411	CcSEcCtD
Nevirapine—Vomiting—Methotrexate—systemic scleroderma	0.000158	0.000382	CcSEcCtD
Nevirapine—Rash—Methotrexate—systemic scleroderma	0.000157	0.000379	CcSEcCtD
Nevirapine—Dermatitis—Methotrexate—systemic scleroderma	0.000157	0.000378	CcSEcCtD
Nevirapine—Headache—Methotrexate—systemic scleroderma	0.000156	0.000376	CcSEcCtD
Nevirapine—Nausea—Methotrexate—systemic scleroderma	0.000148	0.000357	CcSEcCtD
Nevirapine—CYP2B6—skin of body—systemic scleroderma	0.000138	0.0369	CbGeAlD
Nevirapine—CYP1A2—digestive system—systemic scleroderma	0.000115	0.0308	CbGeAlD
Nevirapine—CYP3A5—digestive system—systemic scleroderma	0.000111	0.0297	CbGeAlD
Nevirapine—CYP2B6—digestive system—systemic scleroderma	0.00011	0.0295	CbGeAlD
Nevirapine—CYP2C9—digestive system—systemic scleroderma	0.000109	0.0292	CbGeAlD
Nevirapine—CYP1A2—lung—systemic scleroderma	9.62e-05	0.0257	CbGeAlD
Nevirapine—CYP3A5—lung—systemic scleroderma	9.28e-05	0.0248	CbGeAlD
Nevirapine—CYP2B6—lung—systemic scleroderma	9.22e-05	0.0247	CbGeAlD
Nevirapine—CYP3A4—digestive system—systemic scleroderma	8.34e-05	0.0223	CbGeAlD
Nevirapine—CYP2D6—digestive system—systemic scleroderma	8.21e-05	0.0219	CbGeAlD
